Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
<p>SMG8/9 mutation does not reverse the inhibition of ATR/CHK1 signaling but abrogates ATRi-associated cell-cycle effects, RFS, and TRCs. <b>A,</b> SMG8 and SMG9 mutant cells do not show increased pCHK1 (Ser317 and Ser345) or total CHK1 protein expression levels compared with the W...
Uloženo v:
Podobné jednotky
-
Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Autor: Marta J. Llorca-Cardenosa (14961612)
Vydáno: (2025) -
Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Autor: Marta J. Llorca-Cardenosa (14961612)
Vydáno: (2025) -
Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Autor: Marta J. Llorca-Cardenosa (14961612)
Vydáno: (2025) -
Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Autor: Marta J. Llorca-Cardenosa (14961612)
Vydáno: (2025) -
Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Autor: Arun Kanakkanthara (14937731)
Vydáno: (2025)